



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
23.08.2023 Bulletin 2023/34

(45) Date of publication and mention
of the grant of the patent:
19.07.2023 Bulletin 2023/29

(21) Application number: **16735480.2**

(22) Date of filing: **08.01.2016**

(51) International Patent Classification (IPC):
C07D 498/18 ^(2006.01) **C07D 491/18** ^(2006.01)
A61P 35/00 ^(2006.01) **A61K 47/62** ^(2017.01)
A61K 31/407 ^(2006.01) **A61K 31/4353** ^(2006.01)
A61K 31/436 ^(2006.01) **C12N 9/90** ^(2006.01)

(52) Cooperative Patent Classification (CPC):
C07D 491/18; A61K 31/407; A61K 31/4353;
A61K 31/436; A61K 47/62; A61P 35/00;
C07D 498/18; C12N 9/90; C12Y 502/01008;
A61K 38/00

(86) International application number:
PCT/US2016/012656

(87) International publication number:
WO 2016/112295 (14.07.2016 Gazette 2016/28)

(54) **MACROCYCLIC COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND MEDICAL USES THEREOF**

MAKROZYKLISCHE VERBINDUNGEN MIT BETEILIGUNG AN EINER KOOPERATIVEN BINDUNG UND MEDIZINISCHE VERWENDUNGEN DAVON

COMPOSÉS MACROCYCLIQUES PARTICIPANT À UNE LIAISON COOPÉRATIVE ET LEURS UTILISATIONS MÉDICALES

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **09.01.2015 US 201562101945 P**

(43) Date of publication of application:
29.11.2017 Bulletin 2017/48

(73) Proprietor: **Revolution Medicines, Inc.**
Redwood City, CA 94063 (US)

(72) Inventors:
• **VERDINE, Gregory, Lawrence**
Cambridge, MA 02139 (US)
• **BOWMAN, Brian, Roger**
Cambridge, MA 02139 (US)
• **SOWA, Mathew, Edward**
Brookline, MA 02445 (US)
• **BLODGETT, Joshua Alan, Van Dyke**
Cambridge, MA 02139 (US)

- **ROBISON, Keith, Earl**
Cambridge, MA 02139 (US)
- **STILES, Dylan, Talbot**
Cambridge, MA 02139 (US)
- **MORGENSTERN, Jay, Paul**
Cambridge, MA 02139 (US)
- **TOWNSON, Sharon, Ann**
Cambridge, MA 02139 (US)
- **SHIGDEL, Uddhav, Kumar**
Cambridge, MA 02139 (US)

(74) Representative: **Hoffmann Eitle**
Patent- und Rechtsanwälte PartmbB
Arabellastraße 30
81925 München (DE)

(56) References cited:
EP-A1- 1 079 859 WO-A1-01/36612
WO-A2-2014/187959 US-A1- 2013 072 439

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- **DON BENJAMIN ET AL:** "Rapamycin passes the torch: a new generation of mTOR inhibitors", **NATURE REVIEWS. DRUG DISCOVERY**, vol. 10, no. 11, 31 October 2011 (2011-10-31), pages 868-880, XP55234660, GB ISSN: 1474-1776, DOI: 10.1038/nrd3531
- **Anonymous:** "SMART(TM) Drugs: Engineering Nature's Solution to the Undruggable Target Challenge", , 2016, XP55495775, Retrieved from the Internet:
URL:http://www.warpdrivebio.com/docs/Warp%20Drive%20Bio_SMART%20Drugs%20Platform_2016.pdf [retrieved on 2018-07-27]
- **CHE, Y. ET AL.:** "Inducing protein-protein interactions with molecularglues", **BIOORGANIC & MEDICINAL CHEMISTRY LETTERS**, 2018, pages 1-8, XP55496100, ISSN: 0960-894X, DOI: 10.1016/j.bmcl.2018.04.046